30 closest matches · ranked by relevance
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir · Critically Ill Requiring ECMO and Oseltamivir
Primary: Continuous Venovenous Hemodialysis (CVVHD)Oseltamivir Carboxylate Transmembrane Clearance — 52.2; 43.3 mL/min
End Stage Renal Disease
Primary: Maximum Plasma Concentration (Cmax) of Oseltamivir in HD Participants During Days 1 to 5 — 20.2 ng/mL
Acute Renal Failure
Primary: Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF) — 56; 49…
Influenza
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events(SAEs, AEs Leading to Withdrawal, and Death — 1; 1; 3; 24 Partipants
Bacterial Infections
Primary: Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients — 80.6; 15.9 mcg/mL
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Critically Ill · Hemodialysis
Primary: Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis — 6.3 mL/min
Influenza A
Primary: Clinical Status of Participants on Day 7 — 1; 1; 2; 1 Participants — p=0.181
Influenza · Pneumonia
Primary: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) — 6; 2 Participants — p=.460
Influenza
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs — 40; 50 percentage of participants analyzed — p=0.046
Critical COVID-19 With Respiratory Failure · Acute Respiratory Distress Syndrome (ARDS) · Corona Virus Infection
Primary: Resolution of Respiratory Failure (Alive and Free of Respiratory Failure) — 72; 33 Participants
Influenza
Primary: Area Under the Concentration Versus Time Curve From Time Zero to Last Measurable Plasma Concentration (AUClast) of Oseltamivir and Oseltamivir Carboxylate on Day 1…
Healthy Volunteer
Primary: Total Dialysate Clearance for Automated Peritoneal Dialysis (CLDAPD) of Oseltamivir and Oseltamivir Carboxylate for 75 mg Dose — NA; NA; 0.183; 0.230 Litre (L)/hour (h)
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
Influenza, Human
Primary: Percentage of Participants With Adverse Events — 40.0; 47.3; 25.7; 29.1 percentage of participants
Venous Thromboembolism
Primary: To Determine if an Adjusted-dose of Fondaparinux 2.5 mg Subcutaneously (SQ) q48 hr in Critically Ill Patients With Renal Failure Will Achieve Peak and Trough Levels…
Influenza
Primary: Time to Clinical Stability (Kaplan-Meier Estimate) — 23.7; 37.0; 28.1 hours — p=0.306
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Aspergillosis; Pulmonary, Invasive (Etiology)
Primary: Number of Participants With IAA-infection at ICU Discharge — 2; 4 Participants
Influenza
Primary: Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire…
Influenza, Human
Primary: Time to Clinical Response (TTCR) in Participants With Confirmed Influenza — 5.87; 5.14; 5.63 Days — p=0.25
Influenza
Primary: Percentage of Participants With Adverse Events — 80.4; 67.3; 74.5 percentage of participants
Influenza, Human
Primary: Number of Participants With Any Adverse Event (AE), Drug-related AE, Grade 3 and Grade 4 AE, Grade 3 and 4 Drug-related AE , AE Leading to Discontinuation of Study Drug…
Respiratory Failure
Primary: Number of Participants With Plasma 25(OH)D Concentration >30ng/mL at Baseline — 2; 2; 1 participants
Influenza
Primary: Number of Participants With Laboratory-Confirmed Clinical Influenza, ITT Population — 7; 5 participants — p=0.772
Severe Acute Respiratory Syndrome · Respiratory Failure · Acute Respiratory Distress Syndrome
Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
COVID · Severe Acute Respiratory Syndrome · Sars-CoV2
Primary: To Evaluate the Proportion of Subjects Alive and Free of Respiratory Failure and Free of the Need for Continued Renal Replacement Therapy (RRT) on Day 28 (as Per…
COVID-19 Pneumonia · COVID-19 Respiratory Infection · Acute Respiratory Failure
Primary: Survival — 9; 5 Participants
Influenza
Primary: Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption — 1; 1; 1 number of participants with AEs